Zentalis Pharmaceuticals (ZNTL) Competitors $1.45 -0.04 (-2.68%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. ZVRA, PRME, BCYC, EOLS, REPL, CMPS, RGNX, ARCT, CMPX, and ETONShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Evolus (EOLS), Replimune Group (REPL), COMPASS Pathways (CMPS), REGENXBIO (RGNX), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors Zevra Therapeutics Prime Medicine Bicycle Therapeutics Evolus Replimune Group COMPASS Pathways REGENXBIO Arcturus Therapeutics Compass Therapeutics Eton Pharmaceuticals Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Is ZNTL or ZVRA more profitable? Zevra Therapeutics has a net margin of 4.33% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Zentalis Pharmaceuticals' return on equity of -51.62% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -51.62% -40.28% Zevra Therapeutics 4.33%-112.40%-37.67% Do analysts recommend ZNTL or ZVRA? Zentalis Pharmaceuticals currently has a consensus target price of $5.84, indicating a potential upside of 302.76%. Zevra Therapeutics has a consensus target price of $23.71, indicating a potential upside of 228.00%. Given Zentalis Pharmaceuticals' higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has more volatility and risk, ZNTL or ZVRA? Zentalis Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ZNTL or ZVRA? 35.0% of Zevra Therapeutics shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer ZNTL or ZVRA? In the previous week, Zevra Therapeutics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 4 mentions for Zevra Therapeutics and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.71 beat Zevra Therapeutics' score of 1.27 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, ZNTL or ZVRA? Zevra Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M1.55-$165.84M-$2.26-0.64Zevra Therapeutics$23.61M17.19-$105.51M-$0.21-34.43 SummaryZevra Therapeutics beats Zentalis Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.48M$3.15B$5.80B$10.17BDividend YieldN/A2.32%5.72%4.61%P/E Ratio-0.6421.2475.0526.39Price / Sales1.55466.71544.00190.24Price / CashN/A44.4425.8129.91Price / Book0.319.6413.436.28Net Income-$165.84M-$53.20M$3.29B$270.38M7 Day Performance-9.38%0.07%0.08%1.89%1 Month Performance-8.81%4.27%4.61%6.01%1 Year Performance-60.60%9.62%75.02%25.26% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.9829 of 5 stars$1.45-2.7%$5.84+302.8%-55.2%$107.48M$67.43M-0.64160Positive NewsZVRAZevra Therapeutics2.9987 of 5 stars$8.33-6.9%$23.71+184.7%-7.9%$502.41M$23.61M-39.6720Positive NewsAnalyst DowngradePRMEPrime Medicine3.2941 of 5 stars$3.89+4.6%$8.92+129.2%-2.0%$500.62M$4.96M-1.90234Gap UpBCYCBicycle Therapeutics3.507 of 5 stars$7.00-2.2%$22.22+217.5%-74.6%$495.86M$35.28M-1.99240Positive NewsEOLSEvolus4.0518 of 5 stars$7.61-0.7%$21.25+179.2%-62.1%$495.49M$266.27M-7.77170Positive NewsREPLReplimune Group3.9654 of 5 stars$6.04-4.6%$6.50+7.6%-49.1%$494.09MN/A-1.86210CMPSCOMPASS Pathways3.2503 of 5 stars$4.98-3.1%$16.29+227.0%-29.1%$493.14MN/A-2.71120Positive NewsRGNXREGENXBIO4.5906 of 5 stars$9.48-2.4%$28.38+199.3%-29.2%$490.49M$83.33M-2.76370ARCTArcturus Therapeutics2.8769 of 5 stars$17.84-0.1%$50.57+183.5%-12.6%$484.72M$109.80M-8.00180News CoveragePositive NewsCMPXCompass Therapeutics2.3823 of 5 stars$3.44flat$12.89+274.7%+123.6%$475.69M$850K-7.6420ETONEton Pharmaceuticals2.2882 of 5 stars$17.78+0.6%$29.67+66.9%+245.2%$473.87M$39.01M-111.1320News CoveragePositive News Related Companies and Tools Related Companies ZVRA Competitors PRME Competitors BCYC Competitors EOLS Competitors REPL Competitors CMPS Competitors RGNX Competitors ARCT Competitors CMPX Competitors ETON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts